A pneumonia outbreak associated with a new coronavirus of probable bat origin

Authors:
Peng Zhou,#1 Xing-Lou Yang,#1 Xian-Guang Wang,#2 Ben Hu,1 Lei Zhang,1 Wei Zhang,1 Hao-Rui Si,1,3 Yan Zhu,1 Bei Li,1 Chao-Lin Huang,2 Hui-Dong Chen,2 Jing Chen,1,3 Yun Luo,1,3 Hua Guo,1,3 Ren-Di Jiang,1,3 Mei-Qin Liu,1,3 Ying Chen,1,3 Xu-Rui Shen,1,3 Xi Wang,1,3 Xiao-Shuang Zheng,1,3 Kai Zhao,1,3 Quan-Jiao Chen,1 Fei Deng,1 Lin-Lin Liu,4 Bing Yan,1 Fa-Xian Zhan,4 Yan-Yi Wang,1 Geng-Fu Xiao,1 and Zheng-Li Shi1
In:
Source: Nature
Publication Date: ()
Issue: 579: 7798
Research Area:
Immunotherapy / Hematology
Respiratory Research
Cells used in publication:
HeLa
Species: human
Tissue Origin: cervix
Experiment

Metagenomics analysis of the virus. And they confirmed that 2019-nCoV (SARS-CoV-2) uses the same cell entry receptor—angiotensin converting enzyme II (ACE2)—as SARS-CoV

Abstract

Since the outbreak of severe acute respiratory syndrome (SARS) 18 years ago, a large number of SARS-related coronaviruses (SARSr-CoVs) have been discovered in their natural reservoir host, bats14. Previous studies have shown that some bat SARSr-CoVs have the potential to infect humans57. Here we report the identification and characterization of a new coronavirus (2019-nCoV), which caused an epidemic of acute respiratory syndrome in humans in Wuhan, China. The epidemic, which started on 12 December 2019, had caused 2,794 laboratory-confirmed infections including 80 deaths by 26 January 2020. Full-length genome sequences were obtained from five patients at an early stage of the outbreak. The sequences are almost identical and share 79.6% sequence identity to SARS-CoV. Furthermore, we show that 2019-nCoV is 96% identical at the whole-genome level to a bat coronavirus. Pairwise protein sequence analysis of seven conserved non-structural proteins domains show that this virus belongs to the species of SARSr-CoV. In addition, 2019-nCoV virus isolated from the bronchoalveolar lavage fluid of a critically ill patient could be neutralized by sera from several patients. Notably, we confirmed that 2019-nCoV uses the same cell entry receptor—angiotensin converting enzyme II (ACE2)—as SARS-CoV.